Tacrolimus offered a clinical benefit in medically refractory ulcerative colitis in the short-term, but its long-term effectiveness and safety was found to have important limitations. After 3 months, partial Mayo score had decreased significantly (mean 1.6, P=0.0001), with 36% of patients having partial response and 24% being in clinical remission. One third of patients (35%) suffered adverse events related to the drug (40% tremor, 20% asthenia), leading to discontinuation in 35%. The drug was stopped in 81% of patients after a median of 14 months, with 47% requiring a new immunomodulator, 28% hospitalisation, and 33% colectomy thereafter.
1. Rodriguez-Lago I, et al. ECCO 2019, DOP44.
Posted on
Previous Article
« ABX464: HIV drug tested in ulcerative colitis Next Article
Upadacitinib: data from U-ACHIEVE and CELEST »
« ABX464: HIV drug tested in ulcerative colitis Next Article
Upadacitinib: data from U-ACHIEVE and CELEST »
Table of Contents: ECCO 2019
Featured articles
Interview with Prof. Janneke van der Woude
New Compounds: Study Results
Short-term and Long-term Treatment Results
The right drug for the right patient
Vedolizumab superior to adalimumab in ulcerative colitis
Complementary and Alternative Medicine
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Microbial composition and psychological wellbeing
Remission
Early remission of Crohn’s disease prevents progression
Proactive adalimumab trough measurements
Observational Studies
IBD risk of treatment with IL-17 antagonists
Basic and Preclinical Research
Immune cells and microbes: a happy marriage?
Genetics
Related Articles
May 9, 2019
Pan-Janus kinase inhibitor TD-1473
May 9, 2019
Efficacy and safety of biosimilars
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy